OrthoPediatrics stock gains 3.29 percent as guidance rises

Published on 10/05/2026 at 22:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

OrthoPediatrics stock was last at USD 22.89 on October 5, 2026, while Q2 revenue reached USD 70.5 million, up 15 percent year over year. Analysts set a Moderate Buy consensus with a USD 26.44 target.

KIDS, US68752L1008, Illustration mit AI erstellt.

OrthoPediatrics stock (ISIN US68752L1008) was last at USD 22.89 on Nasdaq on October 5, 2026, up 3.29 percent from the previous close. The move came as investors weighed the companys latest growth figures, raised 2026 revenue guidance and a current analyst consensus.

Revenue reaches USD 70.5 million

For the second quarter of 2026, OrthoPediatrics reported total revenue of USD 70.5 million, an increase of 15 percent from the prior-year quarter, according to The Globe and Mail on August 4, 2026. Adjusted EBITDA reached USD 6.8 million, compared with USD 4.1 million in the second quarter of 2025, while gross margin improved to 74 percent from 72 percent.

The strongest operating contribution came from trauma and deformity revenue, which increased 26 percent to USD 52.6 million. International revenue grew 22 percent to USD 15.7 million, but scoliosis revenue declined 9 percent to USD 16.9 million because the company sold zero 7D units during the quarter and recorded fewer international set sales.

Guidance rises as risks remain

Management raised full-year 2026 revenue guidance to USD 265 million-269 million from USD 263 million-267 million, representing growth of 12 percent to 14 percent, according to The Globe and Mail. The company reiterated adjusted EBITDA guidance of USD 25 million and said it expects free cash flow to reach break-even or better for the full year.

The quarterly mix also shows why execution matters. Scoliosis implants grew at a mid-teens rate, but the absence of 7D sales reduced reported segment revenue. Management also cited timing in international stocking-distributor sales, making the recovery of those channels an important variable for the second half of 2026.

Analysts see room above USD 22.89

MarketBeat reported on September 20, 2026, that 11 analysts assigned OrthoPediatrics a Moderate Buy consensus, with nine Buy ratings, one Hold and one Sell. The average 12-month price target was USD 26.44, placing the target 15.5 percent above the October 5 price.

MarketBeat also reported that BTIG Research reaffirmed a Buy rating and set a USD 29.00 target on September 14, 2026, while Piper Sandler raised its target from USD 22.00 to USD 25.00 on August 5, 2026. These targets frame the market debate, but the negative second-quarter GAAP earnings of USD 0.30 per share and the companys continued product timing risk remain material counterpoints.

OrthoPediatrics stock gains on October 5

OrthoPediatrics stock was last at USD 22.89 on Nasdaq on October 5, 2026, with a session range of USD 22.06 to USD 22.93. The shares remain below the 52-week high of USD 26.74, while market capitalization stood at USD 587.9 million and volume reached 304,772 shares.